Sandres-Saune K - Search Results

1

Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation?

Kamar N, Selves J, Sandres-Saune K, Durand D, Izopet J, Rostaing L. Kamar N, et al. Transplant Proc. 2006 Jun;38(5):1329-32. doi: 10.1016/j.transproceed.2006.02.069. Transplant Proc. 2006. PMID: 16797294

2

Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology.

Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Kamar N, et al. Am J Kidney Dis. 2003 Jul;42(1):184-92. doi: 10.1016/s0272-6386(03)00422-0. Am J Kidney Dis. 2003. PMID: 12830471 Clinical Trial.

3

Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation.

Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. Kamar N, et al. J Am Soc Nephrol. 2003 Aug;14(8):2092-8. doi: 10.1097/01.asn.0000079613.81511.3c. J Am Soc Nephrol. 2003. PMID: 12874463

4

Amantadine therapy in renal transplant patients with hepatitis C virus infection.

Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Kamar N, et al. J Clin Virol. 2004 May;30(1):110-4. doi: 10.1016/j.jcv.2003.10.001. J Clin Virol. 2004. PMID: 15072764 Clinical Trial.

5

Effects of long-term lamivudine therapy in renal-transplant patients.

Kamar N, Sandres-Saune K, Ribes D, Duffaut M, Selves J, Durand D, Izopet J, Rostaing L. Kamar N, et al. J Clin Virol. 2004 Dec;31(4):298-303. doi: 10.1016/j.jcv.2004.07.001. J Clin Virol. 2004. PMID: 15494273

6

Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C.

Kamar N, Borde JS, Sandres-Saune K, Suc B, Barange K, Cointault O, Lavayssière L, Durand D, Izopet J, Rostaing L. Kamar N, et al. Clin Transplant. 2005 Feb;19(1):83-9. doi: 10.1111/j.1399-0012.2004.00302.x. Clin Transplant. 2005. PMID: 15659139

7

Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.

Kamar N, Boulestin A, Selves J, Esposito L, Sandres-Saune K, Stébenet M, Chatelut E, Durand D, Rostaing L, Izopet J. Kamar N, et al. J Med Virol. 2005 May;76(1):61-8. doi: 10.1002/jmv.20323. J Med Virol. 2005. PMID: 15778976

8

Natural history of hepatitis C virus-related liver fibrosis after renal transplantation.

Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, Izopet J. Kamar N, et al. Am J Transplant. 2005 Jul;5(7):1704-12. doi: 10.1111/j.1600-6143.2005.00918.x. Am J Transplant. 2005. PMID: 15943629 Free article.

9

Intrahepatic cytokine profile in renal-transplant patients infected by hepatitis C virus.

Kamar N, Rostaing L, Sandres-Saune K, Selves J, Barthe C, Dubois M, Alric L, Durand D, Izopet J. Kamar N, et al. J Med Virol. 2005 Aug;76(4):482-8. doi: 10.1002/jmv.20387. J Med Virol. 2005. PMID: 15977245

10

[The evolution of the hypervariable region-1 of hepatitis C virus may predict liver fibrosis outcome after renal transplantation].

Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, Izopet J. Kamar N, et al. Nephrol Ther. 2005 Dec;1(6):345-54. doi: 10.1016/j.nephro.2005.08.005. Epub 2005 Nov 7. Nephrol Ther. 2005. PMID: 16895705 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters